Anaplastic Astrocytoma Clinical Trial
Official title:
Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute (NCI) Clinical Research Protocols
The objective of this study is to evaluate patients with tumors of the central nervous system
(CNS) for eligibility in the National Cancer Institute s research studies. These patients
will undergo a series of procedures, usually including a complete medical history and
physical examination; laboratory testing of blood, CSF, urine, bone marrow, or other samples;
an evaluation of tumor location and size by x-rays, CT (computed tomography) or MRI (magnetic
resonance imaging) scans, or nuclear medicine scans; lumbar puncture; electrocardiogram and
echocardiogram; and procedures to evaluate the function of specific organs. A bone marrow
biopsy is occasionally performed. Research samples may also be collected and stored to avoid
having to do a painful test more than once. Tissue specimens collected during this process
may be stored and used in future studies.
Patients of both genders, any age, and all racial and ethnic groups with tumors of the CNS or
a history of a CNS tumor are eligible. Up to 100 people are expected to participate.
The physician will discuss the results of these procedures with the patient and his or her
family. On the basis of the eligibility screening and the patient s wishes, the patient may
then be enrolled in a primary research protocol.
BACKGROUND:
-Adult patients (greater than or equal to 18 yrs of age) with tumors of the central nervous
system who are being evaluated by the Neuro-Oncology Branch (NOB) for National Cancer
Institute (NCI) primary research protocols will be entered onto this screening protocol for
eligibility screening.
OBJECTIVE:
- Evaluate patients with tumors of the Central Nervous System (CNS) for eligibility in
National Cancer Institute (NCI) research protocols.
ELIGIBILITY:
- Patients with tumors of the CNS or a history of a CNS tumor who are being evaluated for
protocols within the National Cancer Institute.
DESIGN:
- The screening tests and procedures that are required by the primary research protocols
will be conducted in order to establish eligibility for these protocols.
- These procedures may include, but are not limited to, laboratory tests on blood, CSF,
urine, or other specimens, and radiographic and nuclear medicine studies, which may
require the administration of contrast or a radioisotopic tracer.
- This protocol will also allow for evaluation of existing tumor specimens to determine if
targets are present, when applicable.
- In some cases, specific research samples required for the primary research protocol may
be collected during the screening process in order to prevent us from having to subject
the patient to a painful procedure on multiple occasions (e.g., bone marrow
aspirations).
- Research specimens will be discarded, if the patient is not eligible for or elects not
to enroll on the primary research protocol. A total of 3000 patients will be enrolled.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01250470 -
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
|
Phase 1 | |
Completed |
NCT01922076 -
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
Recruiting |
NCT01765088 -
A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas
|
Phase 3 | |
Suspended |
NCT01386710 -
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
|
Phase 1/Phase 2 | |
Terminated |
NCT01227434 -
A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
|
Phase 2 | |
Completed |
NCT01171469 -
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
|
Phase 1 | |
Active, not recruiting |
NCT00995007 -
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
|
Phase 2 | |
Not yet recruiting |
NCT06333899 -
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
|
Early Phase 1 | |
Completed |
NCT00879437 -
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
|
Phase 2 | |
Active, not recruiting |
NCT01204684 -
Dendritic Cell Vaccine for Patients With Brain Tumors
|
Phase 2 | |
Recruiting |
NCT03370926 -
FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy
|
N/A | |
Recruiting |
NCT04541082 -
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
|
Phase 1 | |
Completed |
NCT00390299 -
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 1 | |
Recruiting |
NCT01837862 -
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
|
Phase 1/Phase 2 | |
Recruiting |
NCT01269853 -
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
|
Phase 1/Phase 2 | |
Completed |
NCT00612651 -
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
|
Phase 1 | |
Terminated |
NCT03332355 -
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
|
Phase 1 | |
Completed |
NCT03043391 -
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
|
Phase 1 | |
Active, not recruiting |
NCT03581292 -
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
|
Phase 2 | |
Recruiting |
NCT03975829 -
Pediatric Long-Term Follow-up and Rollover Study
|
Phase 4 |